SYNAIRGEN PLC
Developing inhaled interferon beta treatments for severe viral lung infections in hospitalized patients.
SNG | IL
Overview
Corporate Details
- ISIN(s):
- GB00B0381Z20
- LEI:
- 213800IMMTOPPDF8HD24
- Country:
- United Kingdom
- Address:
- MAILPOINT 810 LEVEL F, SO16 6YD SOUTHAMPTON
- Website:
- https://www.synairgen.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Synairgen PLC is a specialist respiratory biotechnology company focused on developing treatments for severe viral lung infections. Founded in 2003 as a spin-off from the University of Southampton, the company's primary focus is its investigative drug candidate, SNG001. This product is an inhaled formulation of interferon beta (IFN-β), a broad-spectrum antiviral protein, designed for direct delivery to the lungs. Synairgen aims to address the significant unmet medical need for effective treatments for hospitalized patients suffering from severe respiratory illnesses caused by viruses like influenza, RSV, and SARS-CoV-2, with a particular focus on patients requiring mechanical ventilation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-04 18:00 |
Business and Financial Review
Business Update
|
English | 26.1 KB | ||
| 2025-05-16 08:00 |
Board/Management Information
Board and Executive Leadership Changes
|
English | 9.8 KB | ||
| 2025-03-28 15:21 |
Post-Annual General Meeting Information
Result of General Meeting
|
English | 18.6 KB | ||
| 2025-03-11 08:00 |
Pre-Annual General Meeting Information
Proposed cancellation of trading on AIM
|
English | 76.3 KB | ||
| 2025-01-17 13:55 |
Major Shareholding Notification
Holding(s) in Company
|
English | 51.8 KB | ||
| 2025-01-16 16:42 |
Board/Management Information
Martin Murphy appointed as Non-Executive Director
|
English | 17.9 KB | ||
| 2025-01-16 16:42 |
Post-Annual General Meeting Information
Result of General Meeting and Total Voting Rights
|
English | 13.5 KB | ||
| 2025-01-15 18:37 |
Share Issue/Capital Change
£18m raised to fund Phase 2 INVENT clinical trial
|
English | 14.8 KB | ||
| 2024-12-20 08:00 |
Share Issue/Capital Change
Proposed Fundraising
|
English | 398.7 KB | ||
| 2024-10-30 19:09 |
Share Issue/Capital Change
Exercise of Share Options and Total Voting Rights
|
English | 10.5 KB | ||
| 2024-10-10 18:05 |
Post-Annual General Meeting Information
Results of AGM and Appointment of New Chairman
|
English | 10.8 KB | ||
| 2024-09-26 08:00 |
Interim Report
Interim Results
|
English | 143.5 KB | ||
| 2024-09-18 08:00 |
Board/Management Information
Appointment of New Chairman and Notice of AGM
|
English | 17.7 KB | ||
| 2024-09-05 08:00 |
Board/Management Information
Board Change
|
English | 11.1 KB | ||
| 2024-06-27 08:00 |
Earnings Release
2023 Full Year Results
|
English | 129.1 KB |
Automate Your Workflow. Get a real-time feed of all SYNAIRGEN PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SYNAIRGEN PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SYNAIRGEN PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
%20Co.%2C%20Ltd/other/SLSBioSpecialty_Lab_Solution_Bio_Co._Ltd-logo.jpg){kind=logo}
